 (Br_J Ophthalmol 1995; 79: 683-686) 
DXS451
The loci DXS 16 and DXS43 yielded informative results (Fig 1) . However, both loci are located on a chromosomal segment distal to the RS gene. Thus, DNA diagnosis could not DXS207 be carried out with sufficient reliability because DXS999 of a lack of useful polymorphic markers proxi-DXS365 mal to RS. Reliable DNA diagnosis became DXS451 possible by using CA repeat polymorphisms (DXS207, DXS999, DXS443, DXS365, and family DXS451), all of which yielded informative results (Fig 1) . In the pedigree, the XLRS disease phenotype cosegregates, in general, A) and the with the alleles F (DXS16)-P (DXS43)-B ted at Johns (DXS207)-A (DXS999)-A (DXS443)-B Monument (DXS365)-A (DXS451) which can be deter-21205-2100 mined from the haplotypes from patients III-4, '5% level for III-5, and IV-1. Only patient III-3, with the according to haplotype f-p-A-A-A-B-A, is recombinant for DXS16, DXS43, and DXS207. Assuming no double recombination, female III-6 inherited an X chromosome from her father, which, for the RS gene region, is characterised by the suggest the alleles f-p-C-A-C-C-B. Thus, her maternal .S9,(DXS16-X chromosome can be identified by the alleles 3-DXS365-f-p-A-B-B-A-C. Since the X chromosome S92-Xcen.13 carrying the mutated RS gene in this pedigree i was found can be identified by the alleles F-P-B-A-A-B-A, (Zmax:'459). III-6 is probably not a carrier for this disease ic map of the entity. The probability for which she is a car-9 is located rier is 0% plus the chance of the occurrence of 3, which is a double recombinant between the RS gene ial interval. and flanking markers DXS207 and DXS443.
Without taking the segregation of DXS999 into account, the latter risk would equal the maximum probability of a single recombinant between DXS207 and RS (0-21; see Table 1 ) times the maximum probability of a single 095% Het Initially, DNA analysis was carried out with conventional DNA probes corresponding to the loci DXS9, DXS16, DXS28, DXS41, DXS43, DXS85, all of which yielded uninformative results (not shown). Recently, the newly available CA repeat polymorphisms were applied. All loci yielded informative results (Fig 2) .
The phase of the X chromosomal markers apparently associated with the XLRS phenotype is suggested by the haplotype of patient IV-1 (C (DXS207)-A (DXS999)-C (DXS443)-B (DXS365)-C (DXS451)). The phase of the markers is confirmed after closer inspection of the genotype of obligate carrier III-1. Since III-1 inherited the alleles B-A-D-C-C from II-1, the other, disease associated maternal alleles are indeed represented by C-A-C-B-C.
Thus, the disease associated chromosome with the grandmother (II-2) is also identified by the alleles C-A-C-B-C, unless a recombination in the Xp22.2 region has occurred with the segregation of chromosomes from II-2 to III-1 (a priori this is not known). However, the phase of the markers in II-2 is confirmed by the allele patterns in II-3 and III-2. Although it is a priori not known if III-2 is a carrier, she did inherit the haplotype C-C-A-A-B from II-3. Thus, her other alleles (B-B-C-C-A) must be from maternal origin, which confirms the phase assignment in II-2.
Further analysis of the genotype of III-2 reveals that she inherited the maternal X chromosome B-B-C-C-A, which is not associated with the disease locus. Therefore, it is highly unlikely that she is a carrier for XLRS unless a double recombination has occurred between RS flanking markers. Based on the segregation patterns of the fully informative RS flanking loci DXS207 and DXS365, the chance for a double recombinant would be 021 times 0 15. Thus, the risk of III-2 being a carrier is less than 3 15%. Additional loci (DXS443, DXS999, and DXS451) can be used to confirm the segregation patterns and to improve the risk estimate. Taking the segregation of these additional markers into account the actual carrier risk estimate for III-2 is less than 0 1%. 
